MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Firm” or “BioRestorative”) (NASDAQ:BRTX), a life sciences firm centered on stem cell-based therapies, in the present day introduced that Robert Paccasassi has been appointed Vice President of High quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead high quality initiatives by the subsequent section of the Firm’s development as affected person enrollment is initiated for the Part 2 scientific trial to deal with persistent lumbar disc illness.
Mr. Paccasassi has over 25 years of biotech operations and mixed expertise in High quality Assurance, Regulatory Compliance, and Manufacturing. Previous to becoming a member of BioRestorative, Mr. Paccasassi held the position of Director, Company High quality Techniques (GMP) at Merck KGaA (Germany). Moreover, he additionally held High quality and Compliance roles at Regeneron Prescription drugs, Millennium Prescription drugs and Biogen Idec.. Mr. Paccasassi obtained his B.S. in Medical Expertise/Biology from the College of Rhode Island and an MBA from Johnson and Wales College.
Mr. Paccasassi can be chargeable for BioRestorative’s cGMP High quality Management and Regulatory Compliance operations as they relate to the Firm’s product pipeline.
“We’re lucky to have Bob in a management position overseeing our high quality and compliance actions.” stated Lance Alstodt, CEO of BioRestorative. “Bob brings quite a lot of experience to the group, offering capabilities and self-discipline to our already sturdy high quality techniques.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic merchandise utilizing cell and tissue protocols, primarily involving grownup stem cells. Our two core packages, as described under, relate to the therapy of disc/backbone illness and metabolic problems:
• Disc/Backbone Program (brtxDISC™): Our lead cell remedy candidate, BRTX-100, is a product formulated from autologous (or an individual’s personal) cultured mesenchymal stem cells collected from the affected person’s bone marrow. We intend that the product can be used for the non-surgical therapy of painful lumbosacral disc problems or as a complementary therapeutic to a surgical process. The BRTX-100 manufacturing course of makes use of proprietary know-how and includes amassing a affected person’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient process, BRTX-100 is to be injected by a doctor into the affected person’s broken disc. The therapy is meant for sufferers whose ache has not been alleviated by non-invasive procedures and who doubtlessly face the prospect of surgical procedure. Now we have obtained authorization from the Food and Drug Administration to begin a Part 2 scientific trial utilizing BRTX-100 to deal with persistent decrease again ache arising from degenerative disc illness.
• Metabolic Program (ThermoStem®): We’re growing a cell-based remedy candidate to focus on weight problems and metabolic problems utilizing brown adipose (fats) derived stem cells to generate brown adipose tissue (“BAT”). BAT is meant to imitate naturally occurring brown adipose depots that regulate metabolic homeostasis in people. Preliminary preclinical analysis signifies that elevated quantities of brown fats in animals could also be chargeable for extra caloric burning in addition to lowered glucose and lipid ranges. Researchers have discovered that individuals with greater ranges of brown fats could have a lowered threat for weight problems and diabetes.
This press launch comprises “forward-looking statements” throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, and such forward-looking statements are made pursuant to the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. You might be cautioned that such statements are topic to a mess of dangers and uncertainties that might trigger future circumstances, occasions or outcomes to vary materially from these projected within the forward-looking statements on account of numerous components and different dangers, together with, with out limitation, these set forth within the Firm’s newest Kind 10-Ok filed with the Securities and Alternate Fee. You need to think about these components in evaluating the forward-looking statements included herein, and never place undue reliance on such statements. The forward-looking statements on this launch are made as of the date hereof and the Firm undertakes no obligation to replace such statements.
E mail: email@example.com